Potential cognitive decline linked to angiotensin-converting enzyme gene but not hypertension: Evidence from
Li-Min Liou1, Yuan-Han Yang2, Shiang-Ru Lu1
1Department of Neurology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Taiwan; Department of Neurology, Kaohsiung Medical University Hospital, Taiwan.
Objectives:
The aims of the present study were to investigate the effect of hypertension and angiotensin-converting enzyme (ACE) genotypes on cognitive event-related potentials (ERPs), and whether the impact of ACE genotypes on P300 is related to the influence of hypertension.
Methods:
Using the Cognitive Abilities Screening Instrument (CASI), we recruited 97 mentally healthy middle-aged and older adults. Medical histories were collected, and blood pressure, ACE insertion/deletion polymorphisms and ERPs in an auditory oddball task were measured for all participants.
Results:
When the participants were stratified according to the presence or absence of hypertension, there were no differences in CASI score, percentage of ACE genotypes and ERPs. The subjects with the D/D homozygote displayed lower amplitude and longer latency of P300, although there were no differences in CASI score and the percentage of hypertension.
Conclusions:
The subjects with the D/D genotype tended to have decreased amplitude and prolonged latency of P300 ERPs which reflected subtle cognitive impairment. There were no associations between hypertension, CASI score and P300 measurements.
Significance:
Using ERPs, potential cognitive decline was linked to ACE genotypes, independently of the effect of hypertension.
Related Concept Videos
Cognitive Development During Adulthood
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Hypertension II: Pathophysiology


